PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34787160-4	2021	Thus, four potential drugs (bromhexine, camostat, gabexate, and nafamostat) were used to explore the mechanism of binding with TMPRSS2 in this work.	Bromhexine	28-38	transmembrane serine protease 2	Homo sapiens	127-134	
34075338-0	2021	Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach.	Bromhexine	125-149	transmembrane serine protease 2	Homo sapiens	48-55	
34075338-5	2021	Hence, we have used a molecular dynamics (MD) simulated homology model of TMPRSS2 to study the inhibition mechanism of experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride (BHH) using molecular modeling techniques.	Bromhexine	185-209	transmembrane serine protease 2	Homo sapiens	74-81	
34075338-5	2021	Hence, we have used a molecular dynamics (MD) simulated homology model of TMPRSS2 to study the inhibition mechanism of experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride (BHH) using molecular modeling techniques.	Bromhexine	211-214	transmembrane serine protease 2	Homo sapiens	74-81	
34075338-7	2021	Molecular docking analysis revealed that Camostat mesylate and its structural analogue Nafamostat interact strongly with residues His296 and Ser441 present in the catalytic triad of TMPRSS2, whereas BHH binds with Ala386 along with other residues.	Bromhexine	199-202	transmembrane serine protease 2	Homo sapiens	182-189	
35103059-1	2022	Background: Bromhexine hydrochloride has been suggested as a TMPRSS2 protease blocker that precludes the penetration of SARS-CoV-2 into cells.	Bromhexine	12-36	transmembrane serine protease 2	Homo sapiens	61-68	
35521985-6	2022	Bromhexine is a specific TMPRSS2 inhibitor that potentially inhibits the infectivity cycle of SARS-CoV-2.	Bromhexine	0-10	transmembrane serine protease 2	Homo sapiens	25-32	
35521985-8	2022	The findings of these studies have shown that bromhexine is effective in improving the clinical outcomes of COVID-19 and has prophylactic effects by inhibiting TMPRSS2 and viral penetration into the host cells.	Bromhexine	46-56	transmembrane serine protease 2	Homo sapiens	160-167	
32824674-6	2020	Clinical studies on TMPRSS2 inhibitors, such as camostat, nafamostat, and bromhexine, are ongoing.	Bromhexine	74-84	transmembrane serine protease 2	Homo sapiens	20-27	
33996911-1	2021	Camostat, nafamostat, and bromhexine are inhibitors of the transmembrane serine protease TMPRSS2.	Bromhexine	26-36	transmembrane serine protease 2	Homo sapiens	89-96	
33608407-10	2021	Paradoxically, Bromhexine enhanced cell-cell fusion in the presence of TMPRSS2, while its metabolite Ambroxol exhibited inhibitory activity in some conditions.	Bromhexine	15-25	transmembrane serine protease 2	Homo sapiens	71-78	
33608407-13	2021	Bromhexine, reportedly an inhibitor of TMPRSS2, is currently tested in clinical trials against coronavirus disease 2019.	Bromhexine	0-10	transmembrane serine protease 2	Homo sapiens	39-46	
33722999-1	2021	BACKGROUND: Bromhexine is a potent inhibitor of transmembrane serine protease 2 and appears to have an antiviral effect in controlling influenza and parainfluenza infection; however, its efficacy in COVID-19 is controversial.	Bromhexine	12-22	transmembrane serine protease 2	Homo sapiens	48-79	
32458206-5	2020	Using bromhexine at a dosage that selectively inhibits TMPRSS2 and, in so doing, inhibits TMPRSS2-specific viral entry is likely to be effective against SARS-CoV-2.	Bromhexine	6-16	transmembrane serine protease 2	Homo sapiens	55-62	
32741259-7	2020	Camostat and bromhexine are known TMPRSS2 inhibitor drugs, hence these were used as control molecules throughout the study.	Bromhexine	13-23	transmembrane serine protease 2	Homo sapiens	34-41	
32458206-5	2020	Using bromhexine at a dosage that selectively inhibits TMPRSS2 and, in so doing, inhibits TMPRSS2-specific viral entry is likely to be effective against SARS-CoV-2.	Bromhexine	6-16	transmembrane serine protease 2	Homo sapiens	90-97	
32360584-0	2020	Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2.	Bromhexine	36-60	transmembrane serine protease 2	Homo sapiens	142-173	
32334052-0	2020	Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection.	Bromhexine	75-85	transmembrane serine protease 2	Homo sapiens	48-55